ABL Diagnostics falls below the 95% threshold

ABL Diagnostics, a company specializing in molecular diagnostics, announces that its main shareholder, Advanced Biological Laboratories (ABL) SA, has reduced its stake to 93.58% of the share capital. This reduction results from block sales carried out since 2025. Although lower, this majority stake remains significant at 95.90% of the voting rights.

This change is part of a strategy to increase the free float. ABL aims to enhance the liquidity of the shares and strengthen ABL Diagnostics' visibility among investors. While ABL remains the majority shareholder, the reduction of its stake reflects the group's commitment to fostering a more diversified shareholder base. With this move, ABL maintains its support for the company's international development strategy.